Neurodegeneration in autoimmune demyelination: Recent mechanistic insights reveal novel therapeutic targets

Journal of Neuroimmunology

Volumn 184, Issue 1-2, 2007, Pages 17-26

  Aktas, Orhan ^a   Waiczies, Sonia ^a   Zipp, Frauke ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

EAE; EGCG; HMG CoA reductase; MS; Neuronal damage; TRAIL

Indexed keywords

EPIGALLOCATECHIN GALLATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ALLERGIC ENCEPHALOMYELITIS; AUTOIMMUNE DISEASE; CENTRAL NERVOUS SYSTEM; DEMYELINATION; GENE TARGETING; HUMAN; MEDICAL RESEARCH; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; TISSUE INJURY;

ACYL COENZYME A; ANIMALS; CATECHIN; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; T-LYMPHOCYTES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 33847635657     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2006.11.026     Document Type: Review

References (130)

1. Afaq F., Adhami V.M., Ahmad N., and Mukhtar H. Inhibition of ultraviolet B-mediated activation of nuclear factor kappaB in normal human epidermal keratinocytes by green tea constituent (-)-epigallocatechin-3-gallate. Oncogene 22 (2003) 1035-1044
2. Ahmad N., Feyes D.K., Nieminen A.L., Agarwal R., and Mukhtar H. Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J. Natl. Cancer Inst. 89 (1997) 1881-1886
3. Aktas O., Waiczies S., Smorodchenko A., Dorr J., Seeger B., Prozorovski T., Sallach S., Endres M., Brocke S., Nitsch R., and Zipp F. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J. Exp. Med. 197 (2003) 725-733
4. Aktas O., Prozorovski T., Smorodchenko A., Savaskan N.E., Lauster R., Kloetzel P.-M., Infante-Duarte C., Brocke S., and Zipp F. Green tea epigallocatechin-3-gallate mediates T cellular NF-κB inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J. Immunol. 173 (2004) 5794-5800
5. Aktas O., Smorodchenko A., Brocke S., Infante-Duarte C., Topphoff U.S., Vogt J., Prozorovski T., Meier S., Osmanova V., Pohl E., Bechmann I., Nitsch R., and Zipp F. Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. Neuron 46 (2005) 421-432
6. Aktas O., Prozorovski T., and Zipp F. Death ligands and autoimmune demyelination. Neuroscientist 12 (2006) 305-316
7. Albert M.A., Danielson E., Rifai N., and Ridker P.M. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 286 (2001) 64-70
8. Angelov D.N., Waibel S., Guntinas-Lichius O., Lenzen M., Neiss W.F., Tomov T.L., Yoles E., Kipnis J., Schori H., Reuter A., Ludolph A., and Schwartz M. Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 4790-4795
9. Arnold D.L., De Stefano N., Matthews P.M., and Trapp B.D. N-acetylaspartate: usefulness as an indicator of viable neuronal tissue. Ann. Neurol. 50 (2001) 823-825
10. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., Blackie C., Chang L., McMurtrey A.E., Hebert A., DeForge L., Koumenis I.L., Lewis D., Harris L., Bussiere J., Koeppen H., Shahrokh Z., and Schwall R.H. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104 (1999) 155-162
11. Banati R.B., Newcombe J., Gunn R.N., Cagnin A., Turkheimer F., Heppner F., Price G., Wegner F., Giovannoni G., Miller D.H., Perkin G.D., Smith T., Hewson A.K., Bydder G., Kreutzberg G.W., Jones T., Cuzner M.L., and Myers R. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 123 (2000) 2321-2337
12. Bechmann I. Failed central nervous system regeneration: a downside of immune privilege?. Neuromolecular Med. 7 (2005) 217-228
13. Benner E.J., Mosley R.L., Destache C.J., Lewis T.B., Jackson-Lewis V., Gorantla S., Nemachek C., Green S.R., Przedborski S., and Gendelman H.E. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 9435-9440
14. Bielekova B., Goodwin B., Richert N., Cortese I., Kondo T., Afshar G., Gran B., Eaton J., Antel J., Frank J.A., McFarland H.F., and Martin R. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 6 (2000) 1167-1175
15. Bitsch A., Schuchardt J., Bunkowski S., Kuhlmann T., and Brück W. Acute axonal injury in multiple sclerosis:correlation with demyelination and inflammation. Brain 123 (2000) 1174-1183
16. Bjartmar C., Wujek J.R., and Trapp B.D. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J. Neurol. Sci. 206 (2003) 165-171
17. Bo L., Vedeler C.A., Nyland H., Trapp B.D., and Mork S.J. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult. Scler. 9 (2003) 323-331
18. Bo L., Vedeler C.A., Nyland H.I., Trapp B.D., and Mork S.J. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J. Neuropathol. Exp Neurol 62 (2003) 723-732
19. Bosel J., and Endres M. Direct neuronal effects of statins. Nervenarzt 77 (2006) 289-293
20. Bosel J., Gandor F., Harms C., Synowitz M., Harms U., Djoufack P.C., Megow D., Dirnagl U., Hortnagl H., Fink K.B., and Endres M. Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones. J. Neurochem. 92 (2005) 1386-1398
21. Botti R.E., Triscari J., Pan H.Y., and Zayat J. Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects. Clin. Neuropharmacol. 14 (1991) 256-261
22. Boussiotis V.A., Freeman G.J., Taylor P.A., Berezovskaya A., Grass I., Blazar B.R., and Nadler L.M. p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes. Nat. Med. 6 (2000) 290-297
23. Brex P.A., Ciccarelli O., O'Riordan J.I., Sailer M., Thompson A.J., and Miller D.H. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N. Engl. J. Med. 346 (2002) 158-164
24. Brosnan C.F., and Raine C.S. Mechanisms of immune injury in multiple sclerosis. Brain Pathol. 6 (1996) 243-257
25. Cantarella G., Uberti D., Carsana T., Lombardo G., Bernardini R., and Memo M. Neutralization of TRAIL death pathway protects human neuronal cell line from beta-amyloid toxicity. Cell Death Differ. 10 (2003) 134-141
26. Cepok S., Rosche B., Grummel V., Vogel F., Zhou D., Sayn J., Sommer N., Hartung H.P., and Hemmer B. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain 128 (2005) 1667-1676
27. Charcot J.M. Lecons sur les maladies du systeme nerveux faites a la Salpetrière. 4 edn (1880) Bourneville, Paris
28. Charo I.F., and Ransohoff R.M. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354 (2006) 610-621
29. Chen J., Zhang Z.G., Li Y., Wang Y., Wang L., Jiang H., Zhang C., Lu M., Katakowski M., Feldkamp C.S., and Chopp M. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann. Neurol. 53 (2003) 743-751
30. Choi J.Y., Park C.S., Kim D.J., Cho M.H., Jin B.K., Pie J.E., and Chung W.G. Prevention of nitric oxide-mediated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease in mice by tea phenolic epigallocatechin 3-gallate. Neurotoxicology 23 (2002) 367-374
31. Chung F.L., Schwartz J., Herzog C.R., and Yang Y.M. Tea and cancer prevention: studies in animals and humans. J. Nutr. 133 (2003) 3268S-3274S
32. Coles A.J., Wing M.G., Molyneux P., Paolillo A., Davie C.M., Hale G., Miller D., Waldmann H., and Compston A. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann. Neurol. 46 (1999) 296-304
33. Cordle A., Koenigsknecht-Talboo J., Wilkinson B., Limpert A., and Landreth G. Mechanisms of statin-mediated inhibition of small G-protein function. J. Biol. Chem. 280 (2005) 34202-34209
34. Danesh F.R., Sadeghi M.M., Amro N., Philips C., Zeng L., Lin S., Sahai A., and Kanwar Y.S. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: Implications for diabetic nephropathy. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 8301-8305
35. Dawson J. The histology of disseminated sclerosis. Trans. R. Soc. Edinb. 50 (1916) 517-740
36. Diem R., Sattler M.B., Merkler D., Demmer I., Maier K., Stadelmann C., Ehrenreich H., and Bahr M. Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis. Brain 128 (2005) 375-385
37. Diestel A., Aktas O., Hackel D., Hake I., Meier S., Raine C.S., Nitsch R., Zipp F., and Ullrich O. Activation of microglial poly(ADP-ribose)-polymerase-1 by cholesterol breakdown products during neuroinflammation: a link between demyelination and neuronal damage. J. Exp. Med. 198 (2003) 1729-1740
38. Dietschy J.M., and Turley S.D. Cholesterol metabolism in the brain. Curr. Opin. Lipidol. 12 (2001) 105-112
39. Dörr J., Bechmann I., Waiczies S., Aktas O., Walczak H., Krammer P.H., Nitsch R., and Zipp F. Lack of tumor necrosis factor-related apoptosis-inducing ligand but presence of its receptors in the human brain. J. Neurosci. 22 (2002) RC209
40. Dörr J., Waiczies S., Wendling U., Seeger B., and Zipp F. Induction of TRAIL-mediated glioma cell death by human T cells. J. Neuroimmunol. 122 (2002) 117-124
41. Dutta R., McDonough J., Yin X., Peterson J., Chang A., Torres T., Gudz T., Macklin W.B., Lewis D.A., Fox R.J., Rudick R., Mirnics K., and Trapp B.D. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann. Neurol. 59 (2006) 478-489
42. Ehrlich S., Infante-Duarte C., Seeger B., and Zipp F. Regulation of soluble and surface-bound TRAIL in human T cells, B cells, and monocytes. Cytokine 24 (2003) 244-253
43. Endres M., and Laufs U. Discontinuation of statin treatment in stroke patients. Stroke 37 (2006) 2640-2643
44. Eriksson M., Ben Menachem E., and Andersen O. Epileptic seizures, cranial neuralgias and paroxysmal symptoms in remitting and progressive multiple sclerosis. Mult. Scler. 8 (2002) 495-499
45. Fassbender K., Simons M., Bergmann C., Stroick M., Lutjohann D., Keller P., Runz H., Kuhl S., Bertsch T., von Bergmann K., Hennerici M., Beyreuther K., and Hartmann T. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 5856-5861
46. Ferguson B., Matyszak M.K., Esiri M.M., and Perry V.H. Axonal damage in acute multiple sclerosis lesions. Brain 120 (1997) 393-399
47. Frenkel D., Maron R., Burt D.S., and Weiner H.L. Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. J. Clin. Invest. 115 (2005) 2423-2433
48. Frohman E.M., Racke M.K., and Raine C.S. Multiple sclerosis-the plaque and its pathogenesis. N. Engl. J. Med. 354 (2006) 942-955
49. Fulda S., Wick W., Weller M., and Debatin K.-M. Smac agonists sensitize for Apo2L/TRAIL-or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat. Med. 8 (2002) 808-815
50. Garcia-Roman N., Alvarez A.M., Toro M.J., Montes A., and Lorenzo M.J. Lovastatin induces apoptosis of spontaneously immortalized rat brain neuroblasts: involvement of nonsterol isoprenoid biosynthesis inhibition. Mol. Cell. Neurosci. 17 (2001) 329-341
51. Giuliani F., Goodyer C.G., Antel J.P., and Yong V.W. Vulnerability of human neurons to T cell-mediated cytotoxicity. J. Immunol. 171 (2003) 368-379
52. Gold R., Linington C., and Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129 Pt 8 (2006) 1953-1971
53. Greenwood J., Walters C.E., Pryce G., Kanuga N., Beraud E., Baker D., and Adamson P. Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J. 17 (2003) 905-907
54. Greenwood J., Steinman L., and Zamvil S.S. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat. Rev. Immunol. 6 (2006) 358-370
55. Greter M., Heppner F.L., Lemos M.P., Odermatt B.M., Goebels N., Laufer T., Noelle R.J., and Becher B. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat. Med. 11 (2005) 328-334
56. Group THPSC. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
57. Hamelin B.A., and Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol. Sci. 19 (1998) 26-37
58. Haqqi T.M., Anthony D.D., Gupta S., Ahmad N., Lee M.S., Kumar G.K., and Mukhtar H. Prevention of collagen-induced arthritis in mice by a polyphenolic fraction from green tea. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 4524-4529
59. Hengst L., and Reed S.I. Translational control of p27Kip1 accumulation during the cell cycle. Science 271 (1996) 1861-1864
60. Heppner F.L., Greter M., Marino D., Falsig J., Raivich G., Hovelmeyer N., Waisman A., Rulicke T., Prinz M., Priller J., Becher B., and Aguzzi A. Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat. Med. 11 (2005) 146-152
61. Heumann R., Goemans C., Bartsch D., Lingenhohl K., Waldmeier P.C., Hengerer B., Allegrini P.R., Schellander K., Wagner E.F., Arendt T., Kamdem R.H., Obst-Pernberg K., Narz F., Wahle P., and Berns H. Transgenic activation of Ras in neurons promotes hypertrophy and protects from lesion-induced degeneration. J. Cell Biol. 151 (2000) 1537-1548
62. Hilliard B., Wilmen A., Seidel C., Liu T.-S.L., Göke R., and Chen Y. Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis. J. Immunol. 166 (2001) 1314-1319
63. Hobom M., Storch M.K., Weissert R., Maier K., Radhakrishnan A., Kramer B., Bähr M., and Diem R. Mechanisms and time course of neuronal degeneration in experimental autoimmune encephalomyelitis. Brain Pathol. 14 (2004) 148-157
64. Hughes D.A. Control of signal transduction and morphogenesis by Ras. Semin. Cell. Biol. 6 (1995) 89-94
65. Inglese M., Ge Y., Filippi M., Falini A., Grossman R.I., and Gonen O. Indirect evidence for early widespread gray matter involvement in relapsing-remitting multiple sclerosis. Neuroimage 21 (2004) 1825-1829
66. Iragui-Madoz V.J. Electrophysiology of multiple sclerosis. In: Daly D.D., and Pedley T.A. (Eds). Current practice of clinical electroencephalography. 2nd edn. (1990), Raven, New York 708-738
67. Jiang H., Zhang S.I., and Pernis B. Role of CD8+ T cells in murine experimental allergic encephalomyelitis. Science 256 (1992) 1213-1215
68. Jick H., Zornberg G.L., Jick S.S., Seshadri S., and Drachman D.A. Statins and the risk of dementia. Lancet 356 (2000) 1627-1631
69. Katiyar S.K., Challa A., McCormick T.S., Cooper K.D., and Mukhtar H. Prevention of UVB-induced immunosuppression in mice by the green tea polyphenol (-)-epigallocatechin-3-gallate may be associated with alterations in IL-10 and IL-12 production. Carcinogenesis 20 (1999) 2117-2124
70. Kobashigawa J.A., Katznelson S., Laks H., Johnson J.A., Yeatman L., Wang X.M., Chia D., Terasaki P.I., Sabad A., Cogert G.A., Trosian K., Hamilton M.A., Moriguchi J.D., Kawata N., Hage A., Drinkwater D.C., and Stevenson L.W. Effect of pravastatin on outcomes after cardiac transplantation. N. Engl. J. Med. 333 (1995) 621-627
71. Kornek B., Storch M.K., Weissert R., Wallstroem E., Stefferl A., Olsson T., Linington C., Schmidbauer M., and Lassmann H. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am. J. Pathol. 157 (2000) 267-276
72. Kutzelnigg A., Lucchinetti C.F., Stadelmann C., Bruck W., Rauschka H., Bergmann M., Schmidbauer M., Parisi J.E., and Lassmann H. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128 (2005) 2705-2712
73. Kwak B., Mulhaupt F., Myit S., and Mach F. Statins as a newly recognized type of immunomodulator. Nat. Med. 6 (2000) 1399-1402
74. Lee S., Suh S., and Kim S. Protective effects of the green tea polyphenol (-)-epigallocatechin gallate against hippocampal neuronal damage after transient global ischemia in gerbils. Neurosci. Lett. 287 (2000) 191-194
75. Lenardo M.J., Chan F.K., Hornung F., McFarland H.F., Siegel R., Wang J., and Zheng L. Mature T lymphocyte apoptosis - immune regulation in a dynamic and unpredictable antigenic environment. Annu. Rev. Immunol. 17 (1999) 221-253
76. Levites Y., Weinreb O., Maor G., Youdim M.B., and Mandel S. Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J. Neurochem. 78 (2001) 1073-1082
77. Liang Y.C., Lin-Shiau S.Y., Chen C.F., and Lin J.K. Inhibition of cyclin-dependent kinases 2 and 4 activities as well as induction of Cdk inhibitors p21 and p27 during growth arrest of human breast carcinoma cells by (-)-epigallocatechin-3-gallate. J. Cell Biochem. 75 (1999) 1-12
78. Liao J.K. Isoprenoids as mediators of the biological effects of statins. J. Clin. Invest. 110 (2002) 285-288
79. Linker R.A., Sendtner M., and Gold R. Mechanisms of axonal degeneration in EAE-lessons from CNTF and MHC I knockout mice. J. Neurol Sci. 233 (2005) 167-172
80. Lu Y.P., Lou Y.R., Xie J.G., Peng Q.Y., Liao J., Yang C.S., Huang M.T., and Conney A.H. Topical applications of caffeine or (-)-epigallocatechin gallate (EGCG) inhibit carcinogenesis and selectively increase apoptosis in UVB-induced skin tumors in mice. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 12455-12460
81. Lünemann J.D., Waiczies S., Ehrlich S., Wendling U., Seeger B., Kamradt T., and Zipp F. Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells. J. Immunol. 168 (2002) 4881-4888
82. MacMicking J.D., Willenborg D.O., Weidemann M.J., Rockett K.A., and Cowden W.B. Elevated secretion of reactive nitrogen and oxygen intermediates by inflammatory leukocytes in hyperacute experimental autoimmune encephalomyelitis: enhancement by the soluble products of encephalitogenic T cells. J. Exp. Med. 176 (1992) 303-307
83. Maron D.J., Fazio S., and Linton M.F. Current perspectives on statins. Circulation 101 (2000) 207-213
84. Martin-Villalba A., Herr I., Jeremias I., Hahne M., Brandt R., Vogel J., Schenkel J., Herdegen T., and Debatin K.-M. CD95 ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons. J. Neurosci. 19 (1999) 3809-3817
85. Mathiesen H.K., Jonsson A., Tscherning T., Hanson L.G., Andresen J., Blinkenberg M., Paulson O.B., and Sorensen P.S. Correlation of global N-acetyl aspartate with cognitive impairment in multiple sclerosis. Arch. Neurol. 63 (2006) 533-536
86. Meske V., Albert F., Richter D., Schwarze J., and Ohm T.G. Blockade of HMG-CoA reductase activity causes changes in microtubule-stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer's disease. Eur. J. Neurosci. 17 (2003) 93-102
87. Meyer R., Weissert R., Diem R., Storck M.K., de Graaf K.L., Kramer B., and Bähr M. Acute neuronal apoptosis in a rat model of multiple sclerosis. J. Neurosci. 21 (2001) 6214-6220
88. Miura Y., Misawa N., Kawano Y., Okada H., Inagaki Y., Yamamoto N., Ito M., Yagita H., Okumura K., Mizusawa H., and Koyanagi Y. Tumor necrosis factor-related apoptosis-inducing ligand induces neuronal death in a murine model of HIV central nervous system infection. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 2777-2782
89. Mukhtar H., and Ahmad N. Green tea in chemoprevention of cancer. Toxicol. Sci. 52 (1999) 111-117
90. Muraro P.A., Wandinger K.P., Bielekova B., Gran B., Marques A., Utz U., McFarland H.F., Jacobson S., and Martin R. Molecular tracking of antigen-specific T cell clones in neurological immune-mediated disorders. Brain 126 (2003) 20-31
91. Nam S., Smith D.M., and Dou Q.P. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J. Biol. Chem. 276 (2001) 13322-13330
92. Neuhaus O., Strasser-Fuchs S., Fazekas F., Kieseier B.C., Niederwieser G., Hartung H.P., and Archelos J.J. Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology 59 (2002) 990-997
93. Neuhaus O., Stuve O., Zamvil S.S., and Hartung H.P. Are statins a treatment option for multiple sclerosis?. Lancet Neurol 3 (2004) 369-371
94. Neumann H., Medana I.M., Bauer J., and Lassmann H. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci. 25 (2002) 313-319
95. Nitsch R., Bechmann I., Deisz R.A., Haas D., Lehmann T.N., Wendling U., and Zipp F. Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Lancet 356 (2000) 827-828
96. Nitsch R., Pohl E.E., Smorodchenko A., Infante-Duarte C., Aktas O., and Zipp F. Direct impact of T cells on neurons revealed by two-photon microscopy in living brain tissue. J. Neurosci. 24 (2004) 2458-2464
97. Noseworthy J.H., Lucchinetti C.F., Rodriguez M., and Weinshenker B.G. Multiple sclerosis. N. Engl. J. Med. 343 (2000) 938-952
98. Palinski W. Immunomodulation: a new role for statins?. Nat. Med. 6 (2000) 1311-1312
99. Peterson J.W., Bo L., Mork S., Chang A., and Trapp B.D. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann. Neurol. 50 (2001) 389-400
100. Pitt D., Werner P., and Raine C.S. Glutamate excitotoxicity in a model of multiple sclerosis. Nat. Med. 6 (2000) 67-70
101. Pooler A.M., Xi S.C., and Wurtman R.J. The 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitor pravastatin enhances neurite outgrowth in hippocampal neurons. J. Neurochem. 97 (2006) 716-723
102. Qiu M.S., Pitts A.F., Winters T.R., and Green S.H. ras isoprenylation is required for ras-induced but not for NGF-induced neuronal differentiation of PC12 cells. J. Cell Biol. 115 (1991) 795-808
103. Rea T.D., Breitner J.C., Psaty B.M., Fitzpatrick A.L., Lopez O.L., Newman A.B., Hazzard W.R., Zandi P.P., Burke G.L., Lyketsos C.G., Bernick C., and Kuller L.H. Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch. Neurol. 62 (2005) 1047-1051
104. Ridker P.M., Rifai N., Clearfield M., Downs J.R., Weis S.E., Miles J.S., and Gotto A.M. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N. Engl. J. Med. 344 (2001) 1959-1965
105. Ryan L.A., Peng H., Erichsen D.A., Huang Y., Persidsky Y., Zhou Y., Gendelman H.E., and Zheng J. TNF-related apoptosis-inducing ligand mediates human neuronal apoptosis: links to HIV-1-associated dementia. J. Neuroimmunol. 148 (2004) 127-139
106. Saheki A., Terasaki T., Tamai I., and Tsuji A. In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm. Res. 11 (1994) 305-311
107. Schulz J.G., Bosel J., Stoeckel M., Megow D., Dirnagl U., and Endres M. HMG-CoA reductase inhibition causes neurite loss by interfering with geranylgeranylpyrophosphate synthesis. J. Neurochem. 89 (2004) 24-32
108. Sever P.S., Dahlof B., Poulter N.R., Wedel H., Beevers G., Caulfield M., Collins R., Kjeldsen S.E., Kristinsson A., McInnes G.T., Mehlsen J., Nieminen M., O'Brien E., and Ostergren J. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
109. Simons M., Keller P., De Strooper B., Beyreuther K., Dotti C.G., and Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 6460-6464
110. Smith K.J., Kapoor R., Hall S.M., and Davies M. Electrically active axons degenerate when exposed to nitric oxide. Ann. Neurol. 49 (2001) 470-476
111. Smith T., Groom A., Zhu B., and Turski L. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat. Med. 6 (2000) 62-66
112. Sparks D.L., Sabbagh M.N., Connor D.J., Lopez J., Launer L.J., Browne P., Wasser D., Johnson-Traver S., Lochhead J., and Ziolwolski C. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch. Neurol. 62 (2005) 753-757
113. Stanislaus R., Pahana K., Singhb A.K., and Singh I. Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin. Neurosci. Lett. 269 (1999) 71-74
114. Stanislaus R., Singh A.K., and Singh I. Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis. J. Neurosci. Res. 66 (2001) 155-162
115. Steinman L. A few autoreactive cells in an autoimmune infiltrate control a vast population of nonspecific cells: a tale of smart bombs and the infantry. Proc. Natl. Acad. Sci. U. S. A. 93 (2002) 2253-2256
116. Steinman L. Optic neuritis, a new variant of experimental encephalomyelitis, a durable model for all seasons, now in its seventieth year. J. Exp. Med. 197 (2003) 1065-1071
117. Suganuma M., Okabe S., Sueoka N., Sueoka E., Matsuyama S., Imai K., Nakachi K., and Fujiki H. Green tea and cancer chemoprevention. Mutat. Res. 428 (1999) 339-344
118. Sun D., Qin Y., Chluba J., Epplen J.T., and Wekerle H. Suppression of experimentally induced autoimmune encephalomyelitis by cytolytic T-T cell interactions. Nature 332 (1988) 843-845
119. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R.A., Mork S., and Bo L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338 (1998) 278-285
120. Uberti D., Cantarella G., Facchetti F., Cafici A., Grasso G., Bernardini R., and Memo M. TRAIL is expressed in the brain cells of Alzheimer's disease patients. NeuroReport 15 (2004) 579-581
121. Vollmer T., Key L., Durkalski V., Tyor W., Corboy J., Markovic-Plese S., Preiningerova J., Rizzo M., and Singh I. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363 (2004) 1607-1608
122. Waiczies S., Prozorovski T., Infante-Duarte C., Hahner A., Aktas O., Ullrich O., and Zipp F. Atorvastatin induces T cell anergy via phosphorylation of ERK1. J. Immunol. 174 (2005) 5630-5635
123. Waiczies S., Prozorovski T., and Zipp F. Modulating T cell signaling cascades by HMG-CoA reductase inhibitors. Signal Transduct. 5 (2005) 231-244
124. Waxman S.G. Nitric oxide and the axonal death cascade. Ann. Neurol. 53 (2003) 150-153
125. Wekerle H., Linington C., Lassmann H., and Meyermann R. Cellular immune reactivity within the CNS. Trends Neurosci. 9 (1986) 271-277
126. Wolozin B., Kellman W., Ruosseau P., Celesia G.G., and Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57 (2000) 1439-1443
127. Yang G.Y., Liao J., Kim K., Yurkow E.J., and Yang C.S. Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols. Carcinogenesis 19 (1998) 611-616
128. Zacco A., Togo J., Spence K., Ellis A., Lloyd D., Furlong S., and Piser T. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. J. Neurosci. 23 (2003) 11104-11111
129. Zamrini E., McGwin G., and Roseman J.M. Association between statin use and Alzheimer's disease. Neuroepidemiology 23 (2004) 94-98
130. Zipp, F., Aktas, O., in press. The brain as a target of inflammatory processes: common pathways link inflammatory and neurodegenerative diseases. Trends Neurosci. 29, 518-527.